NRIX
Nurix Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website nurixtx.com
- Employees(FY) 297
- ISIN US67080M1036
Performance
+2.65%
1W
-19.31%
1M
-5.89%
3M
+40.69%
6M
+113.76%
YTD
+162.31%
1Y
Profile
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing DeTIL-0255, a drug-enhanced investigational cell therapy product that uses NX-0255 ex vivo to enhance tumor infiltrating lymphocytes propagation and phenotypic characteristics. The company has a strategic collaboration agreement with Gilead Sciences, Inc. to discover, develop, and commercialize a pipeline of protein degradation drugs for patients with cancer and other challenging diseases; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
Technical Analysis of NRIX 2024-12-10
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-12-09 18:00
- 2024-12-09 05:00
- 2024-12-06 08:36
- 2024-12-04 13:10
- 2024-12-02 07:00
- 2024-12-01 18:00
- 2024-11-25 07:00
- 2024-11-24 18:00
- 2024-11-20 17:45
- 2024-11-20 16:00
- 2024-11-20 03:00
- 2024-11-17 10:30
- 2024-11-16 21:30
- 2024-11-05 09:00
- 2024-11-04 20:00
- 2024-10-31 07:00
- 2024-10-30 19:00
- 2024-10-24 11:13
- 2024-10-21 16:00
- 2024-10-21 05:45
Nurix Therapeutics’ NX-5948 shows promise in Waldenstrom’s macroglobulinaemia trial(Clinical Trials Arena)
- 2024-10-21 04:00
- 2024-10-19 08:00
- 2024-10-18 20:00
- 2024-10-16 16:35
- 2024-10-16 04:35
- 2024-10-14 07:47
- 2024-10-11 17:10
- 2024-10-11 16:21
- 2024-10-11 16:00
- 2024-10-11 08:01
Page 1 of 9
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.